| Overview |
| bsm-61284r-100ul |
| Smac Recombinant Antibody |
| WB, FCM, IHC-P, IHC-F, IF(IHC-P), IF(ICC), IP |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DIABLO |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cytoplasm |
| SMAC; DFNA64; DIABLO; SMAC3. |
| Promotes apoptosis by activating caspases in the cytochrome c/Apaf-1/caspase-9 pathway. Acts by opposing the inhibitory activity of inhibitor of apoptosis proteins (IAP). Inhibits the activity of BIRC6/bruce by inhibiting its binding to caspases. Isoform 3 attenuates the stability and apoptosis-inhibiting activity of XIAP/BIRC4 by promoting XIAP/BIRC4 ubiquitination and degradation through the ubiquitin-proteasome pathway. Isoform 3 also disrupts XIAP/BIRC4 interacting with processed caspase-9 and promotes caspase-3 activation. Isoform 1 is defective in the capacity to down-regulate the XIAP/BIRC4 abundance. |
| Application Dilution |
| WB |
1:500-2000 |
| FCM |
FCM1:50-100 |
| IHC-P |
IHC-P1:50-200 |
| IHC-F |
IHC-F1:50-200 |
| IF(IHC-P) |
IFIHC-P1:50-200 |
| IF(ICC) |
IFICC1:50-200 |
| IP |
IP1:20-50 |